Company: TVRD
Filing Date: 2025-05-13
Form Type: 8-K/A
Source: 0001104659-25-047844
Chunk: 1

Company: Tvardi Therapeutics, Inc.
Filing Date: 2025-05-13
Form: 8-K/A
Chunk 1
---
 Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.¨

Explanatory Note

This Amendment No. 1 on Form 8-K/A (this “Amendment No. 1”) amends the Current Report on Form 8-K filed by Tvardi Therapeutics, Inc. (f/k/a Cara Therapeutics, Inc.) (the “Company”) on April 15, 2025 (the “Original Report”), in which the Company reported, among other events, the completion of the Merger pursuant to which CT Convergence Merger Sub, Inc. merged with and into Tvardi Operating Company, Inc. (f/k/a Tvardi Therapeutics, Inc.) (“Private Tvardi”). This Amendment No. 1 is filed to (i) update Item 2.01 information toreflect Management’s Discussion and Analysis of Financial Condition and Results of Operations of Private Tvardi for the quarter ended March 31, 2025; and (ii) amend the historical financial statements provided under Item 9.01(a) in the Original Report to include the unaudited interim financial statements of Private Tvardi for the quarter ended March 31, 2025. This Amendment No. 1 does not amend any other item of the Original Report or purport to provide an update or a discussion of any developments at the Company subsequent to the filing date of the Original Report.

Capitalized terms used but not defined herein have the meanings given in the Original Report.

Item 2.01. Completion of Acquisition or Disposition of Assets.

Management’s Disclosure and Analysis of Financial Condition and Results of Operations

The Form 10 information in Item 2.01 of the Original Report under the heading “Management’s Discussion and Analysis of Financial Condition and Results of Operations” is hereby amended and supplemented by adding the following: “Management’s Discussion and Analysis of Financial Condition and Results of Operations for Tvardi for the quarter ended March 31, 2025 is set forth in Exhibit 99.7 to this Amendment No. 1, which is incorporated herein by reference.”

Item